Related Experiment Video
Updated: Jun 29, 2026
09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
Genetic variants associated with cisplatin-induced ototoxicity
Jan Oldenburg1, Sophie D Fosså, Tone Ikdahl
1Department of Clinical Cancer Research, The Norwegian Radium Hospital, Rikshospitalet, Montebello, 0310 Oslo, Norway. janolde@ulrik.uio.no
Pharmacogenomics
|October 16, 2008
Summary
Cisplatin chemotherapy causes hearing loss (ototoxicity) that varies greatly between patients due to genetic factors. Identifying these genetic predictors is key for personalized cisplatin treatment strategies.
Area of Science:
- Pharmacogenomics
- Ototoxicity Research
- Cancer Therapeutics
Background:
- Cisplatin is a widely used chemotherapy agent.
- Cisplatin-induced ototoxicity presents significant interindividual variability.
- Genetic factors are implicated as a major contributor to this variability.
Purpose of the Study:
- To review the prevalence, pathophysiology, and quantification of cisplatin-induced ototoxicity.
- To explore the association between genetic variants and cisplatin ototoxicity.
- To highlight recent advancements in phenotyping and genotyping for this field.
Main Methods:
- Literature review focusing on cisplatin ototoxicity and pharmacogenomics.
- Analysis of studies investigating genetic associations with cisplatin-induced hearing loss.
- Discussion of current phenotyping and genotyping methodologies.
Main Results:
- Ototoxicity is a common and severe side effect of cisplatin treatment.
- Significant genetic variations influence cisplatin-induced ototoxicity risk and severity.
- Limited but growing evidence links specific genetic variants to ototoxicity.
Conclusions:
- Understanding genetic predispositions is crucial for mitigating cisplatin ototoxicity.
- Personalized cisplatin treatment strategies can be developed by identifying predictive genetic markers.
- Further research is needed to fully elucidate the genetic landscape of cisplatin-induced ototoxicity.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...